Not available
Quote | REGENXBIO Inc. (NASDAQ:RGNX)
Last: | $15.90 |
---|---|
Change Percent: | -0.19% |
Open: | $15.67 |
Close: | $15.90 |
High: | $16.28 |
Low: | $15.52 |
Volume: | 360,158 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | REGENXBIO Inc. (NASDAQ:RGNX)
2024-04-23 10:29:06 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Edgewise Therapeutics Historical earnings data for Edg...
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD PR Newswire A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustain...
Message Board Posts | REGENXBIO Inc. (NASDAQ:RGNX)
Subject | By | Source | When |
---|---|---|---|
36M share trading float. | crudeoil24 | investorshub | 09/13/2021 11:36:55 AM |
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie | crudeoil24 | investorshub | 09/13/2021 11:27:19 AM |
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likel | StockLearner2011 | investorshub | 06/03/2019 1:00:24 PM |
I believe the buyout is in a distance | StockLearner2011 | investorshub | 05/31/2019 12:31:48 PM |
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-bi | Zmill | investorshub | 05/29/2019 1:41:40 AM |
News, Short Squeeze, Breakout and More Instantly...
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD PR Newswire A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustain...
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days PR Newswire ROCKVILLE, Md. , March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrop...
2024-03-13 08:00:00 ET Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX) , another biotech, the company is making headway with a gene therapy for Duchenne muscular dystr...